Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery

Neuroscience Letters

Volumn 485, Issue 3, 2010, Pages 241-245

  Borelli, Karina Genaro ^a,b   Defensor, Erwin B ^b   Blanchard, D Caroline ^b   Blanchard, Robert J ^b   Griebel, Guy ^c  

^a UNIVERSIDADE FEDERAL DO ABC   (Brazil)

^b UNIVERSITY OF HAWAII   (United States)

^c SANOFI   (France)

Author keywords

Anxiety; Defensive behavior; Tachykinin NK2 receptor antagonist; Ventral hippocampus

Indexed keywords

SAREDUTANT; TACHYKININ;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIORAL RESEARCH; COGNITION; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; EMOTION; HIPPOCAMPUS; MALE; MAZE TEST; MICROINJECTION; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY; VOCALIZATION;

EID: 77957887641     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.09.021     Document Type: Article

References (30)

1. Advenier C., Rouissi N., Nguyen Q.T., Emonds-Alt X., Breliere J.C., Neliat G., Naline E., Regoli D. Neurokinin A (NK2) receptor revisited with SR 48968, a potent non-peptide antagonist. Biochem. Biophys. Res. Commun. 1992, 184:1418-1424.
2. Anseloni V.Z., Brandao M.L. Ethopharmacological analysis of behaviour of rats using variations of the elevated plus-maze. Behav. Pharmacol. 1997, 8:533-540.
3. Baulmann J., Spitznagel H., Herdegen T., Unger T., Culman J. Tachykinin receptor inhibition and c-Fos expression in the rat brain following formalin-induced pain. Neuroscience 2000, 95:813-820.
4. Bannerman D.M., Grubb M., Deacon R.M.J., Yee B.K., Feldon J., Rawlins J.N.P. Ventral hippocampal lesions affect anxiety but not spatial learning. Behav. Brain Res. 2003, 139:197-213.
5. Blanchard D.C., Griebel G., Blanchard R.J. The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. Eur. J. Pharmacol. 2003, 463:97-116.
6. Blanchard D.C., Lee E.M.C., Williams G., Blanchard R.J. Taming of Rattus norvegicus by lesions of the mesencephalic central gray. Physiol. Psychol. 1981, 9:157-163.
7. Blanchard R.J., Yudko E.B., Rodgers R.J., Blanchard D.C. Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety. Behav. Brain Res. 1993, 58:155-165.
8. Dableh L.J., Yashpal K., Rochford J., Henry J.L. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur. J. Pharmacol. 2005, 507:99-105.
9. Emonds-Alt X., Vilain P., Goulaouic P., Proietto V., Van Broeck D., Advenier C., Naline E., Neliat G., Le Fur G., Breliere J.C. A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci. 1992, 50:PL101-106.
10. Fanselow M.S., Dong H. Are the dorsal and ventral hippocampus functionally distinct structures?. Neuron 2010, 65:7-19.
11. Fenoglio K.A., Brunson K.L., Avishai-Eliner S., Chen Y., Baram T.Z. Region-specific onset of handling-induced changes in corticotropin-releasing factor and glucocorticoid receptor expression. Endocrinology 2004, 145:2702-2706.
12. Griebel G., Moindrot N., Aliaga C., Simiand J., Soubrie P. Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neurosci. Biobehav. Rev. 2001, 25:619-626.
13. Griebel G., Perrault G., Soubrie P. Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology (Berl) 2001, 158:241-251.
14. Ji J., Maren S. Hippocampal involvement in contextual modulation of fear extinction. Hippocampus 2007, 17:749-758.
15. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987, 92:180-185.
16. Louis C., Stemmelin J., Boulay D., Bergis O., Cohen C., Griebel G. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol. Biochem. Behav. 2008, 89:36-45.
17. McDonald R.L., Jones J., Richards B., Hong N.S. A Double dissociation of dorsal and ventral hippocampal function on a learning and memory task mediated by the dorsal-lateral striatum. Eur. J. Neurosci. 2006, 24:1789-1801.
18. Micale V., Tamburella A., Leggio G.M., Mazzola C., Li Volsi V., Drago F. Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol. Biochem. Behav. 2008, 90:463-469.
19. Patacchini R., Maggi C.A. Tachykinin receptors and receptor subtypes. Arch. Int. Pharmacodyn. Ther. 1995, 329:161-184.
20. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press., San Diego.
21. Pentkowski N.S., Blanchard D.C., Lever C., Litvin Y., Blanchard R.J. Effects of lesions to the dorsal and ventral hippocampus on defensive behaviors in rats. Eur. J. Neurosci. 2006, 23:2185-2196.
22. Regoli D., Nguyen Q.T., Jukic D. Neurokinin receptor subtypes characterized by biological assays. Life Sci. 1994, 54:2035-2047.
23. Rodgers R.J., Johnson N.J. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 1995, 52:297-303.
24. Saffroy M., Torrens Y., Glowinski J., Beaujouan J.C. Presence of NK2 binding sites in the rat brain. J. Neurochem. 2001, 79:985-996.
25. Salome N., Stemmelin J., Cohen C., Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacol. Biochem. Behav. 2006, 83:533-539.
26. Steinberg R., Alonso R., Griebel G., Bert L., Jung M., Oury-Donat F., Poncelet M., Gueudet C., Desvignes C., Le Fur G., Soubrie P. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J. Pharmacol. Exp. Ther. 2001, 299:449-458.
27. Stratton S.C., Beresford I.J., Harvey F.J., Turpin M.P., Hagan R.M., Tyers M.B. Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box. Eur. J. Pharmacol. 1993, 250:R11-12.
28. Teixeira R.M., Santos A.R., Ribeiro S.J., Calixto J.B., Rae G.A., De Lima T.C. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 1996, 311:7-14.
29. Toth K., Wittner L., Urban Z., Doyle W.K., Buzsaki G., Shigemoto R., Freund T.F., Magloczky Z. Morphology and synaptic input of substance P receptor-immunoreactive interneurons in control and epileptic human hippocampus. Neuroscience 2007, 144:495-508.
30. Walsh D.M., Stratton S.C., Harvey F.J., Beresford I.J., Hagan R.M. The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology (Berl) 1995, 121:186-191.